Who could benefit from having the Oncotype DX® test?
The Oncotype DX Breast Recurrence Score® test was developed to help guide chemotherapy treatment decisions based on the prediction of chemotherapy benefit. By revealing tumour biology beyond clinical-pathological features (tumour grade, tumour size and age of patient), the test provides an additional piece of information about the treatment benefit of chemotherapy for patients who have HR+, HER2- early-stage breast cancer. The Oncotype DX® test can help directing chemotherapy to those patients who will benefit.1-5
Loading component...
Predictive markers can inform treatment decisions1-2,4,6,12-14
Loading component...
Loading component...
* HR+, HER2-, node-negative, early-stage, invasive breast cancer
a do not benefit from the addition of chemotherapy to endocrine therapy
b significantly benefit from the addition of chemotherapy to endocrine therapy
a do not benefit from the addition of chemotherapy to endocrine therapy
b significantly benefit from the addition of chemotherapy to endocrine therapy
Loading component...
a Patients with unknown values were excluded from the analysis
b Low clinical risk:
tumour size ≤3 cm and Grade 1;
tumour size ≤2 cm and Grade 2;
tumour size ≤1 cm and Grade 3
High clinical risk: all other cases with known values for grade and tumour size
b Low clinical risk:
tumour size ≤3 cm and Grade 1;
tumour size ≤2 cm and Grade 2;
tumour size ≤1 cm and Grade 3
High clinical risk: all other cases with known values for grade and tumour size
Loading component...
Loading component...
b Low clinical risk:
N0, T ≤3 cm and Grade 1
N0, T ≤2 cm and Grade 2
N0, T ≤1 cm and Grade 3
N1, T ≤2 cm and Grade 1
High clinical risk: all other cases
N0, T ≤3 cm and Grade 1
N0, T ≤2 cm and Grade 2
N0, T ≤1 cm and Grade 3
N1, T ≤2 cm and Grade 1
High clinical risk: all other cases
Loading component...
Loading component...
Loading component...
Loading component...
Loading component...
a Low clinical risk: tumour size ≤3 cm and Grade 1; tumour size ≤2 cm and Grade 2; tumour size ≤1 cm and Grade 3
High clinical risk: all other cases with known values for grade and tumour size
b Assuming that adjuvant chemotherapy would have been prescribed or not based on clinical risk.
High clinical risk: all other cases with known values for grade and tumour size
b Assuming that adjuvant chemotherapy would have been prescribed or not based on clinical risk.
